Literature DB >> 31601489

Doxycycline-Dependent Self-Inactivation of CRISPR-Cas9 to Temporally Regulate On- and Off-Target Editing.

Anju Kelkar1, Yuqi Zhu1, Theodore Groth2, Gino Stolfa2, Aimee B Stablewski3, Naina Singhi4, Michael Nemeth4, Sriram Neelamegham5.   

Abstract

Exome and deep sequencing of cells treated with a panel of lentiviral guide RNA demonstrate that both on- and off-target editing proceed in a time-dependent manner. Thus, methods to temporally control Cas9 activity would be beneficial. To address this need, we describe a "self-inactivating CRISPR (SiC)" system consisting of a single guide RNA that deactivates the Streptococcus pyogenes Cas9 nuclease in a doxycycline-dependent manner. This enables defined, temporal control of Cas9 activity in any cell type and also in vivo. Results show that SiC may enable a reduction in off-target editing, with less effect on on-target editing rates. This tool facilitates diverse applications including (1) the timed regulation of genetic knockouts in hard-to-transfect cells using lentivirus, including human leukocytes for the identification of glycogenes regulating leukocyte-endothelial cell adhesion; (2) genome-wide lentiviral sgRNA (single guide RNA) library applications where Cas9 activity is ablated after allowing pre-determined editing times. Thus, stable knockout cell pools are created for functional screens; and (3) temporal control of Cas9-mediated editing of myeloid and lymphoid cells in vivo, both in mouse peripheral blood and bone marrow. Overall, SiC enables temporal control of gene editing and may be applied in diverse application including studies that aim to reduce off-target genome editing.
Copyright © 2019 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CRISPR; Cas9; doxycycline; exome sequencing; genome editing; genome-wide screen; hematopoietic stem cells; lentivirus; next generation sequencing; off target editing

Mesh:

Substances:

Year:  2019        PMID: 31601489      PMCID: PMC6952177          DOI: 10.1016/j.ymthe.2019.09.006

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  61 in total

1.  CRISPR-Cas9 knockin mice for genome editing and cancer modeling.

Authors:  Randall J Platt; Sidi Chen; Yang Zhou; Michael J Yim; Lukasz Swiech; Hannah R Kempton; James E Dahlman; Oren Parnas; Thomas M Eisenhaure; Marko Jovanovic; Daniel B Graham; Siddharth Jhunjhunwala; Matthias Heidenreich; Ramnik J Xavier; Robert Langer; Daniel G Anderson; Nir Hacohen; Aviv Regev; Guoping Feng; Phillip A Sharp; Feng Zhang
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582

2.  A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9.

Authors:  Basudeb Maji; Soumyashree A Gangopadhyay; Miseon Lee; Mengchao Shi; Peng Wu; Robert Heler; Beverly Mok; Donghyun Lim; Sachini U Siriwardena; Bishwajit Paul; Vlado Dančík; Amedeo Vetere; Michael F Mesleh; Luciano A Marraffini; David R Liu; Paul A Clemons; Bridget K Wagner; Amit Choudhary
Journal:  Cell       Date:  2019-05-02       Impact factor: 41.582

3.  Fast and sensitive detection of indels induced by precise gene targeting.

Authors:  Zhang Yang; Catharina Steentoft; Camilla Hauge; Lars Hansen; Allan Lind Thomsen; Francesco Niola; Malene B Vester-Christensen; Morten Frödin; Henrik Clausen; Hans H Wandall; Eric P Bennett
Journal:  Nucleic Acids Res       Date:  2015-03-09       Impact factor: 16.971

4.  Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins.

Authors:  Sojung Kim; Daesik Kim; Seung Woo Cho; Jungeun Kim; Jin-Soo Kim
Journal:  Genome Res       Date:  2014-04-02       Impact factor: 9.043

5.  A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia.

Authors:  Konstantinos Tzelepis; Hiroko Koike-Yusa; Etienne De Braekeleer; Yilong Li; Emmanouil Metzakopian; Oliver M Dovey; Annalisa Mupo; Vera Grinkevich; Meng Li; Milena Mazan; Malgorzata Gozdecka; Shuhei Ohnishi; Jonathan Cooper; Miten Patel; Thomas McKerrell; Bin Chen; Ana Filipa Domingues; Paolo Gallipoli; Sarah Teichmann; Hannes Ponstingl; Ultan McDermott; Julio Saez-Rodriguez; Brian J P Huntly; Francesco Iorio; Cristina Pina; George S Vassiliou; Kosuke Yusa
Journal:  Cell Rep       Date:  2016-10-18       Impact factor: 9.423

6.  Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization.

Authors:  Serif Senturk; Nitin H Shirole; Dawid G Nowak; Vincenzo Corbo; Debjani Pal; Alexander Vaughan; David A Tuveson; Lloyd C Trotman; Justin B Kinney; Raffaella Sordella
Journal:  Nat Commun       Date:  2017-02-22       Impact factor: 14.919

7.  GuideScan software for improved single and paired CRISPR guide RNA design.

Authors:  Alexendar R Perez; Yuri Pritykin; Joana A Vidigal; Sagar Chhangawala; Lee Zamparo; Christina S Leslie; Andrea Ventura
Journal:  Nat Biotechnol       Date:  2017-03-06       Impact factor: 54.908

8.  A highly specific SpCas9 variant is identified by in vivo screening in yeast.

Authors:  Antonio Casini; Michele Olivieri; Gianluca Petris; Claudia Montagna; Giordano Reginato; Giulia Maule; Francesca Lorenzin; Davide Prandi; Alessandro Romanel; Francesca Demichelis; Alberto Inga; Anna Cereseto
Journal:  Nat Biotechnol       Date:  2018-01-29       Impact factor: 54.908

9.  High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects.

Authors:  Benjamin P Kleinstiver; Vikram Pattanayak; Michelle S Prew; Shengdar Q Tsai; Nhu T Nguyen; Zongli Zheng; J Keith Joung
Journal:  Nature       Date:  2016-01-06       Impact factor: 49.962

10.  An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting.

Authors:  Jian Cao; Lizhen Wu; Shang-Min Zhang; Min Lu; William K C Cheung; Wesley Cai; Molly Gale; Qi Xu; Qin Yan
Journal:  Nucleic Acids Res       Date:  2016-07-25       Impact factor: 16.971

View more
  12 in total

1.  Treating Cystic Fibrosis with mRNA and CRISPR.

Authors:  Alejandro Da Silva Sanchez; Kalina Paunovska; Ana Cristian; James E Dahlman
Journal:  Hum Gene Ther       Date:  2020-09-08       Impact factor: 5.695

2.  Forward Genetic Screens of Human Glycosylation Pathways Using the GlycoGene CRISPR Library.

Authors:  Anju Kelkar; Theodore Groth; Sriram Neelamegham
Journal:  Curr Protoc       Date:  2022-04

Review 3.  New Directions in Pulmonary Gene Therapy.

Authors:  Amber Vu; Paul B McCray
Journal:  Hum Gene Ther       Date:  2020-09       Impact factor: 4.793

4.  Transcriptional repression of PTEN in neural cells using CRISPR/dCas9 epigenetic editing.

Authors:  C Moses; S I Hodgetts; F Nugent; G Ben-Ary; K K Park; P Blancafort; A R Harvey
Journal:  Sci Rep       Date:  2020-07-09       Impact factor: 4.379

Review 5.  Cas9-directed immune tolerance in humans-a model to evaluate regulatory T cells in gene therapy?

Authors:  Dimitrios Laurin Wagner; Lena Peter; Michael Schmueck-Henneresse
Journal:  Gene Ther       Date:  2021-02-11       Impact factor: 5.250

6.  A GlycoGene CRISPR-Cas9 lentiviral library to study lectin binding and human glycan biosynthesis pathways.

Authors:  Yuqi Zhu; Theodore Groth; Anju Kelkar; Yusen Zhou; Sriram Neelamegham
Journal:  Glycobiology       Date:  2021-04-01       Impact factor: 4.313

Review 7.  Controlling CRISPR with small molecule regulation for somatic cell genome editing.

Authors:  Namita Khajanchi; Krishanu Saha
Journal:  Mol Ther       Date:  2021-06-24       Impact factor: 12.910

Review 8.  Gene Editing by Extracellular Vesicles.

Authors:  Dmitry Kostyushev; Anastasiya Kostyusheva; Sergey Brezgin; Valery Smirnov; Elena Volchkova; Alexander Lukashev; Vladimir Chulanov
Journal:  Int J Mol Sci       Date:  2020-10-05       Impact factor: 5.923

Review 9.  Genetic glycoengineering in mammalian cells.

Authors:  Yoshiki Narimatsu; Christian Büll; Yen-Hsi Chen; Hans H Wandall; Zhang Yang; Henrik Clausen
Journal:  J Biol Chem       Date:  2021-02-20       Impact factor: 5.157

10.  A new mouse SNP genotyping assay for speed congenics: combining flexibility, affordability, and power.

Authors:  Kimberly R Andrews; Samuel S Hunter; Brandi K Torrevillas; Nora Céspedes; Sarah M Garrison; Jessica Strickland; Delaney Wagers; Gretchen Hansten; Daniel D New; Matthew W Fagnan; Shirley Luckhart
Journal:  BMC Genomics       Date:  2021-05-24       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.